Login | SITEMAP | FAQS

about icvs | People | BFMCOSTA

 

Name: Bruno M. Costa

Office: I1.02

School Phone: +351 253 604 872

Email: bfmcosta@med.uminho.pt

 

 

 

Keywords: Neuro-oncology Theranostics Epigenetics Glioma Glioblastoma Cancer Therapy Oncology

About

        Bruno Costa (BC) is an Assistant Researcher working at the Life and Health Sciences Research Institute (ICVS), University of Minho (Portugal).

        He graduated in Applied Biology in 2003 and completed his PhD degree in Health Sciences in December 2008 by the University of Minho. During his PhD studies, BC also worked for 2 years at the UCSF (University of California, San Francisco, USA) under the supervision of Prof. Joseph Costello. Between January 2009 and June 2013, he was a Post-Doc fellow from FCT (Portugal) at the ICVS/3B’s, a Portuguese Associate Laboratory. During his scientific career, BC has worked in several research groups in Portugal (University of Porto and University of Minho), in the Netherlands (Leiden University Medical Centre), and in the USA (University of California, San Francisco). In 2013, BC was granted with a FCT Investigator position (starting grant).

        BC is mainly interested in the study of molecular (genetic and epigenetic) and cellular hallmarks of human brain tumors, and how these can be translated into therapeutic and prognostic value, contributing to a precision medicine approach in brain cancer care. Of all brain tumors, glioblastoma (GBM) is particularly devastating, being the most common and most malignant type. The clinical outcomes are very poor and vary greatly among patients. Paradoxically, GBM patients are almost always treated with a “one fits all” standard approach, mostly because good prognostic and drug response biomarkers are still lacking. Using a wide panoply of biological samples, ranging from in vitro and in vivo models, to primary tumor samples obtained from patients, BC has been focused on identifying novel biomarkers of GBM and exploiting novel therapeutic strategies to target oncogenic features.

        BC has accumulated 22 honors/prizes, including prestigious recognitions from the Calouste Gulbenkian Foundation (2010 Award on Cutting Edge Research in Life Sciences), the Luso-American Development Foundation, and the Portuguese League Against Cancer. He was an invited speaker in 23 communications. His work was awarded with 9 best poster/oral communication prizes in scientific meetings. 

        BC is an elected member of the School Council of the School of Medicine since Jan 2015.

Honors and Prizes

2000  Merit Diploma 1999/2000, University of Minho
2001  Merit Diploma 2000/2001, University of Minho
2002  Merit Diploma 2001/2002, University of Minho
2003  Best Student of Applied Biology in 1999-2003, University of Minho
2003  Erasmus Scholarship Award
2005  Portuguese Science Foundation (FCT) PhD scholarship  
2006  Research Fellowship from the Luso-American Development Foundation (FLAD)
2009  Portuguese Science Foundation (FCT) Post-Doc scholarship  
2010  Award from Portuguese League Against Cancer
2010  Award from Calouste Gulbenkian Foundation (Investigação Na Fronteira das Ciências da Vida)
2011  FEBS Youth Travel Grant
2011  Award from Portuguese League Against Cancer
2013  Best Poster Award at the XXII Porto Cancer Meeting
2013  EACR (European Association for Cancer Research) Meeting Bursary Award
2013  Investigator FCT
2014  EMBO sponsorship for Organization of an International Workshop
2014  Best Oral presentation at the VIII Congress of the Portuguese Association of Neuro-Oncology
2016  Best Oral Presentation Prize at the 2nd ASPIC International Congress
2017  Best Oral presentation at the X Congress of the Portuguese Association of Neuro-Oncology
2017  Best Poster Award at the ICVS Open Day - 2017
2018  Best Poster Award at the ICVS Open Day - 2018
2018  Best Poster Award at the 3rd ASPIC (Portuguese Association of Cancer Research) Congress
2019  Best Oral presentation at the X Congress of the Portuguese Association of Neuro-Oncology


10 Selected Publications

         - Costa, B.M., Ferreira P., Costa S., Canedo P., Oliveira P., Silva A., Pardal F., Suriano G., Machado J.C., Lopes J.M., Reis R.M. Association between functional EGF+61 polymorphism and glioma risk. Clin Cancer Res. 2007 May 1;13(9):2621-6.

        - Costa, B.M.; Smith, J.S.; Chen, Y.; Chen, J; Phillips, H.S.; Aldape, K.D.; Zardo, G.; Nigro, J.; James, C.D.; Fridlyand, J.; Reis, R.M.; Costello, J.F. Reversing HOXA9 Oncogene Activation by PI3K Inhibition: Epigenetic Mechanism and Prognostic Significance in Human Glioblastoma. Cancer Research, 2010 Jan 15; 70(2):453-62.

        - Costa, B.M.; Pereira, M.V.; Fernandes, R.; Costa, S.; Silva, A.; Pardal, F.; Amorim, J.; Nabiço, R.; Almeida, R.; Alegria, C.; Pires, M.M.; Pinheiro, C.; Carvalho, E.; Oliveira, P.; Lopes, J.M.; Reis, R.M. “Impact of EGFR Genetic Variants on Glioma Risk and Patient Outcome”. Cancer Epidemiology, Biomarkers & Prevention, 2011 Dec; 20(12):2610-7.

        - Butowski, N.; Chang, S.M.; Lamborn, K.R.; Polley, M.Y.; Pieper, R.; Costa B.M.; Reis, R. M.; Costello, J.F.; Vandenberg, S.; Parvataneni, R.; Nicole, A.; Kazmierski, M.H.; Nicol, S.J.; Thornton, D.E.; Prados, M.D. “Phase II and Pharmacogenomics Study of Enzastaurin plus Temozolomide During and Following Radiation Therapy in Patients with Newly Diagnosed Glioblastoma Multiforme and Gliosarcoma”. Neuro-Oncology, 2011 Dec;13(12):1331-8.

        - Pojo M, Gonçalves CS, Xavier-Magalhães A, Oliveira AI, Gonçalves T, Correia S, Rodrigues AJ, Costa S, Pinto L, Pinto AA, Lopes JM, Reis RM, Rocha M, Sousa N, Costa BM. A Transcriptomic Signature Mediated by HOXA9 Promotes Human Glioblastoma Initiation, Aggressiveness and Resistance to Temozolomide. Oncotarget 2015, Apr 10;6(10):7657-74

        
- Vieira de Castro J, Gomes ED, Granja S, Anjo SI, Baltazar F, Manadas B, Salgado AJ, Costa BM. Impact of mesenchymal stem cells' secretome on glioblastoma pathophysiology. J Transl Med. 2017 Oct 2;15(1):200.

        - Oliveira AI, Anjo SI, Vieira de Castro J, Serra SC, Salgado AJ, Manadas B, Costa BM. Crosstalk between glial and glioblastoma cells triggers the "go-or-grow" phenotype of tumor cells. Cell Commun Signal. 2017 Oct 2;15(1):37

        - Xavier-Magalhães A, Gonçalves CS, Fogli A, Lourenço T, Pojo M, Pereira B, Rocha M, Lopes MC, Crespo I, Rebelo O, Tão H, Lima J, Moreira R, Pinto http:// AA, Jones C, Reis RM, Costello JF, Arnaud P, Sousa N, Costa BM. The long non-coding RNA HOTAIR is transcriptionally activated by HOXA9 and is an independent prognostic marker in patients with malignant glioma. Oncotarget. 2018 Feb 28;9(21):15740-15756

        - Gonçalves CS, Vieira de Castro J, Pojo M, Martins EP, Queirós S, Chautard E, Taipa R, Pires MM, Pinto AA, Pardal F, Custódia C, Faria CC, Clara C, Reis RM, Sousa N, Costa BM. WNT6 is a Novel Oncogenic Prognostic Biomarker in Human Glioblastoma. Theranostics 2018; 8(17):4805-4823.

        - Mancini A, Xavier-Magalhães A, Woods WS, Nguyen KT, Amen AM, Hayes JL, Fellman C, Gapinske M, McKinney AM, Hong C, Jones LE, Walsh KM, Bell RJA, Doudna JA, Costa BM, Song JS, Perez-Pinera P, Costello JF. Disruption of the ß1L isoform of GABP reverses glioblastoma replicative immortality in a TERT promoter mutation-dependent manner. Cancer Cell, 2018 Sep 10;34(3):513-528.e8


Full List of Publications (PubMed direct link)

 

Selected Publications

Costa BM, Smith JS, Chen Y, Chen J, Phillips HS, Aldape KD, Zardo G, Nigro J, James CD, Fridlyand J, Reis RM, Costello JF. Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma. Cancer Res. 2010 Jan 15;70(2):453-62. doi: 10.1158/0008-5472.CAN-09-2189. Epub 2010 Jan 12.

Butowski N, Chang SM, Lamborn KR, Polley MY, Pieper R, Costello JF, Vandenberg S, Parvataneni R, Nicole A, Sneed PK, Clarke J, Hsieh E, Costa BM, Reis RM, Hristova-Kazmierski M, Nicol SJ, Thornton DE, Prados MD. Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. Neuro Oncol. 2011 Dec;13(12):1331-8. doi: 10.1093/neuonc/nor130. Epub 2011 Sep 6.

Pojo M, Gonçalves CS, Xavier-Magalhães A, Oliveira AI, Gonçalves T, Correia S, Rodrigues AJ, Costa S, Pinto L, Pinto AA, Lopes JM, Reis RM, Rocha M, Sousa N, Costa BM. A transcriptomic signature mediated by HOXA9 promotes human glioblastoma initiation, aggressiveness and resistance to temozolomide. Oncotarget, 6(10):7657-7674 (2015).

Costa BM, Viana-Pereira M, Fernandes R, Costa S, Linhares P, Vaz R, Pinheiro C, Lima J, Soares P, Silva A, Pardal F, Amorim J, Nabiço R, Almeida R, Alegria C, Pires MM, Pinheiro C, Carvalho E, Oliveira P, Lopes JM, Reis RM. Impact of EGFR genetic variants on glioma risk and patient outcome. Cancer Epidemiol Biomarkers Prev. 2011 Dec;20(12):2610-7. doi: 10.1158/1055-9965.EPI-11-0340. Epub 2011 Sep 29.

Costa BM1, Ferreira P, Costa S, Canedo P, Oliveira P, Silva A, Pardal F, Suriano G, Machado JC, Lopes JM, Reis RM. Association between functional EGF+61 polymorphism and glioma risk. Clin Cancer Res. 2007 May 1;13(9):2621-6.

Copyright © 2012-2016 ICVS. All rights reserved.